Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Medtronic
Express Scripts
UBS
Fish and Richardson
Boehringer Ingelheim
Moodys
Merck

Generated: October 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020700

« Back to Dashboard

NDA 020700 describes MUSE, which is a drug marketed by Mylan Speciality Lp and is included in one NDA. It is available from one supplier. Additional details are available on the MUSE profile page.

The generic ingredient in MUSE is alprostadil. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the alprostadil profile page.
Summary for 020700
Tradename:MUSE
Applicant:Mylan Speciality Lp
Ingredient:alprostadil
Patents:0
Pharmacology for NDA: 020700
Medical Subject Heading (MeSH) Categories for 020700
Suppliers and Packaging for NDA: 020700
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MUSE alprostadil SUPPOSITORY;URETHRAL 020700 NDA Meda Pharmaceuticals 0037-8110 0037-8110-06 6 POUCH in 1 CARTON (0037-8110-06) > 1 SUPPOSITORY in 1 POUCH (0037-8110-01)
MUSE alprostadil SUPPOSITORY;URETHRAL 020700 NDA Meda Pharmaceuticals 0037-8120 0037-8120-06 6 POUCH in 1 CARTON (0037-8120-06) > 1 SUPPOSITORY in 1 POUCH (0037-8120-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUPPOSITORY;URETHRALStrength0.125MG
Approval Date:Nov 19, 1996TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:SUPPOSITORY;URETHRALStrength0.25MG
Approval Date:Nov 19, 1996TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:SUPPOSITORY;URETHRALStrength0.5MG
Approval Date:Nov 19, 1996TE:RLD:Yes

Expired US Patents for NDA 020700

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Speciality Lp MUSE alprostadil SUPPOSITORY;URETHRAL 020700-001 Nov 19, 1996 ➤ Sign Up ➤ Sign Up
Mylan Speciality Lp MUSE alprostadil SUPPOSITORY;URETHRAL 020700-004 Nov 19, 1996 ➤ Sign Up ➤ Sign Up
Mylan Speciality Lp MUSE alprostadil SUPPOSITORY;URETHRAL 020700-003 Nov 19, 1996 ➤ Sign Up ➤ Sign Up
Mylan Speciality Lp MUSE alprostadil SUPPOSITORY;URETHRAL 020700-003 Nov 19, 1996 ➤ Sign Up ➤ Sign Up
Mylan Speciality Lp MUSE alprostadil SUPPOSITORY;URETHRAL 020700-004 Nov 19, 1996 ➤ Sign Up ➤ Sign Up
Mylan Speciality Lp MUSE alprostadil SUPPOSITORY;URETHRAL 020700-001 Nov 19, 1996 ➤ Sign Up ➤ Sign Up
Mylan Speciality Lp MUSE alprostadil SUPPOSITORY;URETHRAL 020700-002 Nov 19, 1996 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
QuintilesIMS
Baxter
Merck
Queensland Health
Chubb
Fish and Richardson
Julphar
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.